Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.

Abstract:

:Parkinson disease (PD) is a progressive, disabling, neurodegenerative disorder characterized by both motor and nonmotor symptoms. Monoamine oxidase B inhibitors, dopamine agonists, N-methyl-D-aspartate antagonists and levodopa (LD), with its various formulations and administration modes, mainly improve the motor symptoms in PD, which are thought to be related to decreased dopamine levels in the brain. Of these therapeutic drug options, LD represents the most effective and best tolerated compound when it is administered several times a day. Pharmacokinetic trials of oral LD/dopa decarboxylase inhibitor (DDCI) formulations with and without the catechol-O-methyltransferase inhibitor, entacapone, showed that repeated administration with entacapone causes an increase in both the maximum concentration (Cmax) and time to Cmax (Tmax) of LD. In addition, gastrointestinal motility may also impact plasma LD behavior. These peripheral components of LD metabolism contribute to the onset of motor complications, which are predominantly associated with LD/DDCI owing to its short plasma half-life. The increase in Tmax is related to a slower increase in plasma LD concentrations after repeated LD/DDCI intake, which may also increase the risk of wearing off. An elevation in Cmax after reiterated LD intake increases the risk of peak-dose dyskinesia. Therefore, it may be useful to start with higher doses of LD formulations in the morning and then to titrate with different LD doses during the day according to the individual patient's motor behavior, which is particularly characterized by the onset of motor complications, such as off periods and dyskinesia, in more advanced stages of PD.

journal_name

Clin Neuropharmacol

authors

Müller T

doi

10.1097/WNF.0b013e31828f3385

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

84-91

issue

3

eissn

0362-5664

issn

1537-162X

pii

00002826-201305000-00003

journal_volume

36

pub_type

杂志文章,评审
  • An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

    abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/WNF.0b013e3181f8d501

    authors: Anand R,Geffen Y,Vasile D,Dan I

    更新日期:2010-11-01 00:00:00

  • Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

    abstract::The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.wnf.0000168581.97083.9c

    authors: Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

    更新日期:2005-05-01 00:00:00

  • Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

    abstract::A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199310000-00004

    authors: Gomez-Mancilla B,Bédard PJ

    更新日期:1993-10-01 00:00:00

  • A review of the antiepileptic drug tiagabine.

    abstract::Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schachter SC

    更新日期:1999-11-01 00:00:00

  • De Novo Myoclonic Status Epilepticus After Benzodiazepine Withdrawal.

    abstract::Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000283

    authors: Vicente Ferreira Naves P,Calderaro M,Caboclo LO

    更新日期:2018-07-01 00:00:00

  • Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

    abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200101000-00007

    authors: Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

    更新日期:2001-01-01 00:00:00

  • Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report.

    abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000220

    authors: Jeon DG,Kim YW,Kim NY,Park JH

    更新日期:2017-07-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31823da9a8

    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease.

    abstract::Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.wnf.0000150865.21759.bc

    authors: Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

    更新日期:2004-11-01 00:00:00

  • A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain.

    abstract::In this study, the hemodynamic and neurochemical effects of lisuride, a dopamine agonist with serotoninergic properties, have been evaluated in de novo parkinsonian patients and in elderly subjects with mild cognitive impairment. Blood pressure (BP), heart rate (HR), and urinary catecholamine (CA) fluctuations through...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00005

    authors: Micieli G,Martignoni E,Bono G,Cavallini A,Rossi F,Horowski R,Nappi G

    更新日期:1989-10-01 00:00:00

  • Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins.

    abstract:OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.WNF.0000240951.18821.50

    authors: Wohlfarth K,Müller C,Sassin I,Comes G,Grafe S

    更新日期:2007-03-01 00:00:00

  • The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.

    abstract:OBJECTIVES:To determine the effects of treatment with donepezil on cortical metabolism in patients with traumatic brain injury using F-fluorodeoxyglucose positron emission tomography. METHODS:Twenty-six patients with cognitive impairment after traumatic brain injury were enrolled and randomly assigned into the donepez...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0B013E31816F1BC1

    authors: Kim YW,Kim DY,Shin JC,Park CI,Lee JD

    更新日期:2009-03-01 00:00:00

  • Diagnosis and assessment of age-associated memory impairment.

    abstract::Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199013003-00009

    authors: Crook TH,Larrabee GJ,Youngjohn JR

    更新日期:1990-01-01 00:00:00

  • A Pilot Study of Randomized, Head-to-Head of Metformin Versus Topiramate in Obese People With Schizophrenia.

    abstract:OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000188

    authors: Peng PJ,Ho PS,Tsai CK,Huang SY,Liang CS

    更新日期:2016-11-01 00:00:00

  • Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

    abstract::Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200211000-00002

    authors: Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

    更新日期:2002-11-01 00:00:00

  • Levetiracetam is not effective for essential tremor.

    abstract:OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013E31807A32C6

    authors: Elble RJ,Lyons KE,Pahwa R

    更新日期:2007-11-01 00:00:00

  • Memantine Rescues Neurosyphilis-Related Schizophrenic-like Features and Cognitive Deficit.

    abstract:OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000347

    authors: Chen WC,Wang HY,Chen PA,Chen IC,Chen YC

    更新日期:2019-07-01 00:00:00

  • Clinical usefulness of apomorphine in movement disorders.

    abstract::Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199406000-00004

    authors: Colosimo C,Merello M,Albanese A

    更新日期:1994-06-01 00:00:00

  • Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons.

    abstract::Oxidant stress resulting from excess dopamine (DA) may contribute to the development and progression of Parkinson's disease (PD). Free radicals resulting from the enzymatic metabolism of DA are most often discussed in this regard. However, levodopa (L-DOPA) and DA can also undergo autooxidation, producing free radical...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619040-00010

    authors: Ling ZD,Pieri SC,Carvey PM

    更新日期:1996-08-01 00:00:00

  • A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.

    abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.WNF.0000220819.71231.96

    authors: Mauri MC,Colasanti A,Rossattini M,Moliterno D,Baldi ML,Papa P

    更新日期:2006-05-01 00:00:00

  • Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

    abstract::Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200111000-00006

    authors: Giménez-Roldán S,Esteban EM,Mateo D

    更新日期:2001-11-01 00:00:00

  • Spiking fevers with clozapine treatment.

    abstract::Clozapine often causes low-grade fever and less frequently spiking fever. We describe three cases of spiking fever that occurred in the first 3 weeks of clozapine therapy. A new set of side effects of clozapine is identified, which includes spiking fever, respiratory and gastrointestinal symptoms, and neutrophilia. Po...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199704000-00009

    authors: Trémeau F,Clark SC,Printz D,Kegeles LS,Malaspina D

    更新日期:1997-04-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Is history of depression a contraindication to treatment with tetrabenazine?

    abstract:OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.WNF.0000228369.25593.35

    authors: Kenney C,Hunter C,Mejia N,Jankovic J

    更新日期:2006-09-01 00:00:00

  • Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration.

    abstract::In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199502000-00012

    authors: Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

    更新日期:1995-02-01 00:00:00

  • Neurophysiologic and neuropsychologic profiles of lamotrigine in epilepsy.

    abstract::The anticonvulsant potential of lamotrigine (LTG) has been extensively assessed in open and double-blind clinical trials including patients with different types of epilepsy. In this review, the neurophysiologic and neuropsychologic profile of LTG is discussed. The electroencephalographic (EEG) findings reveal that the...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Marciani MG,Spanedda F,Mattia D

    更新日期:1999-05-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00

  • Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage.

    abstract:BACKGROUND:The cerebellum has traditionally been regarded as an organ of motor coordination. However, the importance of the cerebellum in psychiatric disorders, behavior, and cognition is increasingly being recognized. There is no consensus concerning treatment of schizophrenia-like psychosis after cerebellar pathology...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31821f4d91

    authors: Almeida J,Serrão EM,Almeida AT,Afonso JG

    更新日期:2011-05-01 00:00:00

  • Midazolam in the treatment of refractory neonatal seizures.

    abstract::Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199619020-00005

    authors: Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

    更新日期:1996-04-01 00:00:00